Vivesto AB

    Vivesto AB

    OOTC:OASMY
    - -
    USD
    - -
    - -
    Vivesto AB
    OTC:OASMY
    (OTC Markets)

    Recent

    price

    - -

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2010
    2011
    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    2023
    2024
    2025
    TTM
    SEK
    1.34
    - -
    0.03
    - -
    - -
    0.04
    0.11
    - -
    0.03
    0.02
    1.32
    0.15
    0.01
    - -
    - -
    - -
    - -
    Revenue per Share
    -0.74
    -2.38
    -1.91
    -1.71
    -2.07
    -2.09
    -2.39
    -2.31
    -1.22
    -1.79
    -0.07
    -0.77
    -1.89
    -0.62
    -0.19
    -0.17
    -0.16
    Basic EPS, GAAP
    -4.2
    -5.64
    -3.74
    -3.15
    -2.41
    -2.29
    -2.5
    -2.04
    -1.5
    -1.16
    -0.13
    -1.05
    -0.46
    -0.34
    -0.23
    -0.26
    -0.18
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    -2.38
    -4.3
    -5.36
    -5.99
    -7.07
    -8.46
    -10.41
    -11.19
    -9.18
    -9.74
    -7.1
    -7.9
    -9.15
    -8.91
    -9.1
    -9.27
    -9.03
    Book Value per Share
    -0.31
    2.09
    -1.59
    -0.9
    -2.12
    -0.52
    -1.62
    -2.21
    -1.31
    -0.53
    2.47
    0.64
    0.71
    0.28
    0.11
    -0.09
    0.11
    Tangible Book Value per Share
    23
    28
    34
    42
    51
    56
    59
    69
    97
    112
    153
    172
    189
    206
    206
    206
    206
    Basic Weighted Avg Shares
    31
    - -
    1
    - -
    - -
    2
    6
    - -
    3
    2
    202
    26
    1
    - -
    - -
    - -
    - -
    Sales/Revenue/Turnover
    -48.67
    -60,709.43
    -7,354.77
    - -
    -170,568.33
    -5,234.98
    -2,082.11
    -81,792.44
    -3,278.04
    -7,613.59
    -15.07
    -502.14
    -35,243.55
    - -
    - -
    - -
    - -
    Operating Margin (%)
    4
    5
    5
    5
    5
    5
    5
    5
    5
    31
    20
    29
    252
    57
    3
    2
    1
    Depreciation Expense
    -17
    -66
    -66
    -72
    -105
    -117
    -142
    -160
    -118
    -201
    -11
    -133
    -357
    -129
    -40
    -34
    -33
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    -55.48
    -62,226.42
    -7,370.37
    - -
    -175,186.67
    -5,676.18
    -2,220.92
    -93,164.53
    -3,723.79
    -10,166.92
    -5.22
    -506.73
    -35,134.19
    - -
    - -
    - -
    - -
    Profit Margin (%)
    -12
    46
    -64
    -63
    -131
    -52
    -117
    -171
    -143
    -44
    355
    97
    129
    57
    23
    -19
    23
    Working Capital
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    9
    5
    5
    - -
    - -
    - -
    - -
    LT Debt
    142
    294
    273
    319
    282
    376
    326
    300
    345
    383
    819
    550
    326
    198
    158
    125
    167
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    SEK

    •

    in mil. unless spec.
    Sep'25
    Dec'25
    Mar'26
    ST Debt
    - -
    13
    - -
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    6
    6
    11
    Market Capitalization
    39
    10
    - -

    Working Capital

    SEK

    •

    in mil. unless spec.
    Sep'25
    Dec'25
    Mar'26
    Total Current Assets
    6
    5
    35
    Cash, Cash Equivalents & STI
    1
    2
    31
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    16
    24
    11
    Payables & Accruals
    - -
    - -
    - -
    ST Debt
    - -
    13
    - -
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    SEK

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    -3.56%
    -30.84%
    -21.32%
    Free Cash Flow
    64.01%
    144.32%
    13.58%
    Net Income, GAAP
    116.46%
    236.29%
    -14.27%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    SEK

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    SEK

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    -0.04
    -0.05
    -0.05
    -0.05
    -0.19
    2025
    -0.04
    -0.05
    -0.03
    -0.04
    -0.17
    2026
    - -
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    SEK

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • defenseworld.net

      Financial Survey: Oasmia Pharmaceutical (OTCMKTS:OASMY) versus Acrivon Therapeutics (NASDAQ:ACRV)

    • seekingalpha.com

      Vivesto AB (OASMY) Discusses Pipeline Advancements in Paccal Vet and Cantrixil and Strategic Capital Raise Transcript